
    
      A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome will be evaluated during a double
      blind, placebo controlled study. This study is an expansion of RLP042019 NCT04078841 Treating
      Post-Lyme Disease Syndrome With Acetogenins
    
  